https://www.selleckchem.com/pr....oducts/chir-99021-ct
e 2 or received dose 2 outside of their protocol-defined interval and that the follow-up period was limited to 365 days for most participants. Ad26.ZEBOV, MVA-BN-Filo vaccination was well tolerated and immunogenic in healthy and HIV-infected African adults. Increasing the interval between vaccinations from 28 to 56 days improved the magnitude of humoral immune responses. Antibody levels persisted to at least 1 year, and Ad26.ZEBOV booster vaccination demonstrated the presence of vaccination-induced immune memory. These da